Last reviewed · How we verify
Tislelizumab plus Carboplatin and Paclitaxel
Tislelizumab plus Carboplatin and Paclitaxel is a PD-1 inhibitor and chemotherapeutic agents Small molecule drug developed by RemeGen Co., Ltd.. It is currently in Phase 3 development for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma. Also known as: Tislelizumab plus Platinum-Based Chemotherapy.
Tislelizumab is a monoclonal antibody that targets PD-1, while carboplatin and paclitaxel are chemotherapeutic agents that interfere with DNA replication and cell division.
Tislelizumab is a monoclonal antibody that targets PD-1, while carboplatin and paclitaxel are chemotherapeutic agents that interfere with DNA replication and cell division. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | Tislelizumab plus Carboplatin and Paclitaxel |
|---|---|
| Also known as | Tislelizumab plus Platinum-Based Chemotherapy |
| Sponsor | RemeGen Co., Ltd. |
| Drug class | PD-1 inhibitor and chemotherapeutic agents |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Tislelizumab works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells and thereby unleashing an immune response against the cancer. Carboplatin and paclitaxel, on the other hand, are cytotoxic agents that induce DNA damage and apoptosis in rapidly dividing cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Nausea
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (PHASE2)
- RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) (PHASE3)
- Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (PHASE2)
- SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC (PHASE2, PHASE3)
- Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02) (PHASE1)
- Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma (PHASE3)
- Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tislelizumab plus Carboplatin and Paclitaxel CI brief — competitive landscape report
- Tislelizumab plus Carboplatin and Paclitaxel updates RSS · CI watch RSS
- RemeGen Co., Ltd. portfolio CI
Frequently asked questions about Tislelizumab plus Carboplatin and Paclitaxel
What is Tislelizumab plus Carboplatin and Paclitaxel?
How does Tislelizumab plus Carboplatin and Paclitaxel work?
What is Tislelizumab plus Carboplatin and Paclitaxel used for?
Who makes Tislelizumab plus Carboplatin and Paclitaxel?
Is Tislelizumab plus Carboplatin and Paclitaxel also known as anything else?
What drug class is Tislelizumab plus Carboplatin and Paclitaxel in?
What development phase is Tislelizumab plus Carboplatin and Paclitaxel in?
What are the side effects of Tislelizumab plus Carboplatin and Paclitaxel?
What does Tislelizumab plus Carboplatin and Paclitaxel target?
Related
- Drug class: All PD-1 inhibitor and chemotherapeutic agents drugs
- Target: All drugs targeting PD-1
- Manufacturer: RemeGen Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer, PD-L1 positive
- Indication: Drugs for Head and neck squamous cell carcinoma
- Also known as: Tislelizumab plus Platinum-Based Chemotherapy
- Compare: Tislelizumab plus Carboplatin and Paclitaxel vs similar drugs
- Pricing: Tislelizumab plus Carboplatin and Paclitaxel cost, discount & access